Montreal General Hospital, McGill University Health Centre, Montreal, Quebec H3G 1A4, Canada.
J Rheumatol. 2011 Nov;38(11):2318-25. doi: 10.3899/jrheum.110587. Epub 2011 Sep 15.
We aimed to systematically review rheumatoid arthritis (RA) disease severity indices for use in administrative healthcare databases. We also provide an overview of alternative methods to control for RA disease severity in administrative database research.
We conducted a systematic review of studies that developed/validated an index for RA disease severity using variables in administrative databases, and compared the convergent validity/reliability of the index with a standard measure of RA severity.
After reviewing 539 articles, 2 studies were included. The claims-based index for RA severity (CIRAS) was developed in one study. Components of the CIRAS included tests for inflammatory markers, number of chemistry panels/platelet counts ordered, rheumatoid factor test, number of rehabilitation and rheumatology visits, and Felty's syndrome. The CIRAS correlated moderately well with a previously validated RA medical records-based index of severity. The second study assessed whether current and lifetime treatment with disease-modifying antirheumatic drugs and/or biologics accurately predicted RA severity, as measured by the patient-reported Patient Activity Scale (PAS). Treatment variables did not fully distinguish patients in the highest and lowest quartiles of PAS scores (67.2% correctly classified).
Two claims-based indices of RA severity were identified but have some limitations for routine use. A concerted effort from experts in the field is needed to define, develop, and validate a widely applicable measure of RA disease severity for administrative database research.
我们旨在系统地回顾类风湿关节炎(RA)疾病严重程度指数,以用于医疗保健管理数据库。我们还概述了在管理数据库研究中控制 RA 疾病严重程度的替代方法。
我们对使用管理数据库中的变量开发/验证 RA 疾病严重程度指数的研究进行了系统回顾,并将该指数的收敛有效性/可靠性与 RA 严重程度的标准衡量标准进行了比较。
在审查了 539 篇文章后,纳入了 2 项研究。一项研究中开发了基于索赔的 RA 严重程度指数(CIRAS)。CIRAS 的组成部分包括炎症标志物检测、化学面板/血小板计数的次数、类风湿因子检测、康复和风湿病就诊次数,以及 Felty 综合征。CIRAS 与之前验证的基于 RA 病历的严重程度指数中度相关。第二项研究评估了当前和终身使用疾病修正抗风湿药物和/或生物制剂是否可以准确预测 RA 严重程度,这是通过患者报告的患者活动量表(PAS)来衡量的。治疗变量并不能完全区分 PAS 评分最高和最低四分位数的患者(正确分类 67.2%)。
确定了两种基于索赔的 RA 严重程度指数,但在常规使用方面存在一些局限性。需要领域内的专家共同努力,为管理数据库研究定义、开发和验证广泛适用的 RA 疾病严重程度衡量标准。